ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

APLMW Apollomics Inc

0.0138
0.00 (0.00%)
25 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Apollomics Inc APLMW NASDAQ Warrant Capital Accionario
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 0.0138 15:43:38
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.0138 0.0138
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
04/6/202407:00GLOBEApollomics Announces Vebreltinib Data at the 2024 American..
30/5/202415:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/5/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
29/5/202416:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
29/5/202407:00GLOBEApollomics Announces Presentation at the 2024 BIO..
24/5/202416:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/5/202415:58EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/5/202415:32EDGAR2Form F-3 - Registration statement by foreign private issuers
20/5/202415:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/5/202415:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/5/202415:05GLOBEApollomics Announces Private Placement Financing and..
25/4/202407:30GLOBEApollomics Announces Approval of Vebreltinib in China as a..
10/4/202406:00GLOBEApollomics Presents Vebreltinib Data at the 2024 American..
02/4/202407:00GLOBEApollomics Announces Poster Presentations of Vebreltinib..
28/3/202406:00GLOBEApollomics Highlights Clinical Progress and Reports Full..
26/3/202407:00GLOBEApollomics to Announce Full Year 2023 Financial Results and..
04/3/202406:00GLOBEApollomics Appoints Matthew Plunkett, Ph.D. as Chief..
07/2/202406:00GLOBEApollomics to Present at the Oppenheimer 34th Annual..
19/1/202415:15GLOBEApollomics Receives Nasdaq Notification Regarding Minimum..
17/1/202415:30GLOBEApollomics to Participate in a Fireside Chat at the B. Riley..
03/1/202406:00GLOBEApollomics Completes Enrollment in Phase 3 Bridging Study of..
02/1/202415:30GLOBEApollomics to Present at the 2024 Biotech Showcase
04/12/202306:00GLOBEApollomics Presents Interim Data from Two Ongoing Phase 2..
29/11/202306:30GLOBEApollomics to Participate in a Fireside Chat at the H.C...
28/11/202306:00GLOBEApollomics Announces Presentation of Vebreltinib Data at the..
16/11/202307:30GLOBEApollomics Announces the First Approval of Vebreltinib for..
31/10/202307:30GLOBEApollomics Announces Two New Cohorts in Global Phase 2..
26/10/202307:50GLOBEApollomics Announces Report of Activity of Vebreltinib in..
23/10/202307:30GLOBEApollomics Announces Efficacy of Vebreltinib in NSCLC..
16/10/202317:55GLOBEApollomics Announces Presentations of Vebreltinib Data at..
28/9/202315:17GLOBEApollomics Reports First Half 2023 Financial Results and..
06/9/202306:00GLOBEApollomics to Present at the H.C. Wainwright 25th Annual..

Su Consulta Reciente

Delayed Upgrade Clock